Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporsis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer could be just one step behind Wyeth in getting a new selective estrogen receptor modulator approved and on the market for the treatment of osteoporosis in postmenopausal women. The drug maker has submitted an NDA for Fablyn (lasofoxifene, formerly Oporia) in that indication, development partner Ligand announced Jan. 15.